Chronic Total Occlusion Clinical Trial
— DAPT-CTOOfficial title:
Antiplatelet Therapy After Successful Percutaneous Coronary Intervention for Chronically Occluded Coronary Artery: A Prospective, Multicenter, Randomized Study Comparing Two Durations of Dual Antiplatelet Therapy
Coronary arteries are in charge of oxygen supply for the myocardium. When coronary arteries develop stenosis the coronary blood flow (i.e. oxygen flow) is reduced. Chronic total occlusion (CTO) is the extreme evolution of a coronary stenosis, which ends up to a total vessel closure. Percutaneous coronary intervention (PCI) is the main treatment for chronic occlusions. The principle of this treatment is to implant a stent covering the whole segment of occlusion and allowing the blood to perfuse the myocardium antegradely and not retrogradely via the collateral(s). This angioplasty and stent implantation requires a dual antiplatelet therapy (aspirin associated with clopidogrel) to prevent a new thrombosis within the newly placed coronary stent. Following the development of coronary stent (and particularly drug eluting coronary stent) new thrombosis within the implanted coronary scaffold have emerged. Dual antiplatelet therapy (DAPT) (compared to single antiplatelet therapy or anticoagulant) and initially prolonged DAPT (12 months) has offered a preventive treatment for stent thrombosis after PCI. PCI treatment for CTOs continues to increase in France and around the world, while no dedicated study has been proposed so far regarding DAPT duration. Therefore, the general European recommendations for DAPT in chronic coronary syndrome management guidelines should be applied even though the CTO poses specific technical challenges (long and multiple stenting length for example). Even if 6 months DAPT is recommended as routine duration in chronic coronary syndrome (CCS), longer DAPT (12 months) is possible in this setting. However, the optimal duration of DAPT is not clearly demonstrated on an individual basis and each physician must adapt the DAPT duration for each single patient. A so called "ischemic / bleeding balance "guides the duration of DAPT. This study would be the first randomized protocol to clarify the efficacy and safety of a shorter DAPT duration in the specific context of CTO PCI. It is conceivable that the technical advances which have made it possible to reduce the duration of DAPT to up to 1 month, in the cases of patients at high risk of bleeding for example, could be applicable to CTO PCI. Therefore, reducing the DAPT to 1 month, in the setting of CTO PCI, could reduce the haemorrhagic risk which should be proportional to the duration of the DAPT. Moreover, the invesitgators will evaluate the safety of short DAPT in terms of ischemic events during follow-up.
Status | Not yet recruiting |
Enrollment | 660 |
Est. completion date | September 30, 2027 |
Est. primary completion date | March 30, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients who underwent a successful coronary stent implantation for chronic coronary occlusion, eligible for long-term aspirin therapy and requiring a dual antiplatelet therapy - Affiliated to Social Security system. - Signature of informed consent. - Age > 18 years old. Exclusion Criteria: - Dual antiplatelet therapy contra-indication - Patient with hypersensitivity to aspirin (or any of its excipients) and/or to any of the active substance or to any of the excipients of the investigational medical product used in this study (clopidogrel); - Patient with contraindication to aspirin and/or clopidogrel. - No coronary stent implanted - Age < 18years - Patient under guardianship - Pregnancy or breast feeding - Prasugrel or ticagrelor use |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | bleeding events at 12 months | time-to-composite endpoint of bleeding events will be assessed according to the Bleeding Academic Research Consortium (BARC) Classification (BARC2 to BARC5) during follow-up (12 months). | 12 months | |
Primary | ischemic events at 12 months | time-to-composite endpoint of ischemic events (all cause death, stroke, stent thrombosis, myocardial infarction, repeat revascularization, rehospitalisation for angina) will be recorded during follow-up (12 months). | 12 months | |
Secondary | Major adverse ischemic clinical events (MACE) | time-to-composite endpoint of ischemic stroke, cardiovascular death, stent thrombosis, repeat revascularization, rehospitalisation for angina over 12 months follow-up, taking into account the competing risk of death from non-cardiovascular cause, or time to last follow-up in case of no MACE | 12 months | |
Secondary | Time-to-bleeding | Time-to-bleeding event defined according to Bleeding Academic Research Consortium (BARC) classification (BARC 2 to BARC 5) over 12 months follow up, taking into account the competing risk of death from non-haemorrhagic cause, or time to last follow-up in case of no bleeding event.The BARC classification goes from 0 (no bleeding) to 5b (Fatal bleeding. Overt bleeding, autopsy, or imaging confirmation). | 12 months | |
Secondary | Time-to-all cause death | Time-to-all cause death over 12 months follow-up, or time to last follow-up in case of no death | 12 months | |
Secondary | Compliance to drug regimen at 1 month | Compliance to drug regimen at will be assessed by telephone or during an clinical visit 1 months after the inclusion | 1 month | |
Secondary | Compliance to drug regimen at 6 months | Compliance to drug regimen at will be assessed by telephone or during an clinical visit 6 months after the inclusion | 6 months | |
Secondary | Compliance to drug regimen at 12 months | Compliance to drug regimen at will be assessed by telephone or during an clinical visit 12 months after the inclusion | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05111496 -
Evaluation of the Radiological Dose Delivered to Risky Interventional Cardiology Patients (Optidose)
|
||
Not yet recruiting |
NCT05440084 -
Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity
|
||
Withdrawn |
NCT04059536 -
Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)
|
||
Completed |
NCT05158686 -
Use of Drug-Coated Balloon to Improve Recanalization of a Coronary Chronic Total Occlusion After Failed Angioplasty
|
||
Completed |
NCT03988166 -
Chronic Total Occlusion Percutaneous Coronary Intervention Study
|
N/A | |
Not yet recruiting |
NCT05632653 -
CTO-PCI in Heart Failure Patients
|
N/A | |
Recruiting |
NCT03563989 -
STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion
|
N/A | |
Recruiting |
NCT04710342 -
Clinical Study Evaluating Use of the CapBuster Medical Device System for the Crossing of Chronic Total Occlusions
|
N/A | |
Not yet recruiting |
NCT06358508 -
Sapphire 3 CTO Study
|
N/A | |
Completed |
NCT01246505 -
Peripheral Facilitated Antegrade Steering Technique in Chronic Total Occlusions
|
Phase 3 | |
Recruiting |
NCT05614180 -
Chronic Total Occlusive Lesions CMR Study
|
||
Completed |
NCT04226326 -
Investigating the Utility of Remote Index of Microvascular Resistance in Patients With Chronic Total Occlusion
|
N/A | |
Recruiting |
NCT04533633 -
German Epicardial Collateral CTO Registry
|
||
Recruiting |
NCT04650139 -
Coronary Interventions Ulm - Coronary Chronic Total Occlusions
|
||
Recruiting |
NCT06137521 -
Risk Factors and Outcomes in Coronary Chronic Total Occlusion
|
||
Completed |
NCT02358629 -
A Prospective, Non-randomized Study to Evaluate the Safety and Performance of the NovaCross™ Microcatheter in Femoropopliteal Chronic Total Occlusion (CTO).
|
N/A | |
Completed |
NCT00670436 -
The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions
|
Phase 2 | |
Completed |
NCT04862559 -
A Single Center Study to Evaluate the Safety of the NovaCross Microcatheter in Crossing Chronic Total Occlusions
|
N/A | |
Active, not recruiting |
NCT02227771 -
Consistent CTO Trial
|
N/A | |
Recruiting |
NCT05458999 -
Decreasing Patient Anxiety During Revascularization of Chronic Total Coronary Occlusions Using Virtual Reality Glasses.
|
N/A |